Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 in Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839Phase 1Recruiting
- Sponsor
- Servier
- Start
- Mar 2014
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ivosidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and hematologic malignancy, sponsored by Servier. Primary endpoints: Incidence of Adverse Events at 26 weeks, Maximum Tolerated Dose and/or Recommended Phase II Dose at 26 weeks and 3 more. Started Mar 2014; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)hematologic malignancy
Beyond the preview
Go deeper on NCT02074839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074839.